SEC Form 4 · accession 0001179110-16-026304
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Andrew Davis
Officer — Executive VP & CMO
Period of report
Jun 8, 2016
Accepted (ET)
Jun 9, 2016 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock OptionF1 | $4.72 | Jun 8, 2016 | A | 157,000 | A | Jun 8, 2017 | Jun 8, 2026 | Common Stock | 157,000 | 157,000 | D |
Explanation of responses
- F125% vest on June 8, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.